We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) ended the recent trading session at $44.14, demonstrating a +2.65% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.33%. On the other hand, the Dow registered a gain of 1.08%, and the technology-centric Nasdaq increased by 0.08%.
Shares of the medical device manufacturer witnessed a loss of 2.07% over the previous month, trailing the performance of the Medical sector with its loss of 0.15%, and the S&P 500's gain of 1.41%.
The upcoming earnings release of Boston Scientific will be of great interest to investors. The company's earnings report is expected on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.17 billion, up 2.12% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.24 per share and revenue of $21.17 billion, which would represent changes of +5.88% and +5.45%, respectively, from the prior year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.49% lower. Currently, Boston Scientific is carrying a Zacks Rank of #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 13.28. This expresses a discount compared to the average Forward P/E of 19.61 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.82.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Boston Scientific (BSX - Free Report) ended the recent trading session at $44.14, demonstrating a +2.65% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.33%. On the other hand, the Dow registered a gain of 1.08%, and the technology-centric Nasdaq increased by 0.08%.
Shares of the medical device manufacturer witnessed a loss of 2.07% over the previous month, trailing the performance of the Medical sector with its loss of 0.15%, and the S&P 500's gain of 1.41%.
The upcoming earnings release of Boston Scientific will be of great interest to investors. The company's earnings report is expected on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.17 billion, up 2.12% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.24 per share and revenue of $21.17 billion, which would represent changes of +5.88% and +5.45%, respectively, from the prior year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.49% lower. Currently, Boston Scientific is carrying a Zacks Rank of #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 13.28. This expresses a discount compared to the average Forward P/E of 19.61 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.82.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.